---
id: ITE-2022-134
type: ITE
year: 2022
number: 134
created: 2025-08-08 07:54:57.704058
tags:
- ITE
- question
- ITE-2022
answer: A
topic: null
related_articles:
- title: Mucositis Following an Upper Respiratory Tract Infection.
  path: 2023/2023-11-mucositis-following-an-upper-respiratory-tract-infection.md
  similarity: 0.5
  link: '[[2023/2023-11-mucositis-following-an-upper-respiratory-tract-infection|Mucositis
    Following an Upper Respiratory Tract Infection.]]'
- title: 'Guiding Prescription of Antibiotics in People With Acute Respiratory Infections:
    Biomarkers as Point-of-Care Tests.'
  path: 2023/2023-07-guiding-prescription-of-antibiotics-in-people-with-acute-res.md
  similarity: 0.429
  link: '[[2023/2023-07-guiding-prescription-of-antibiotics-in-people-with-acute-res|Guiding
    Prescription of Antibiotics in People With Acute Respiratory Infections: Biomarkers
    as Point-of-Care Tests.]]'
- title: Procalcitonin for Diagnosis, Risk Assessment, and Prognosis of Respiratory
    Tract Infections.
  path: 2022/2022-09-procalcitonin-for-diagnosis-risk-assessment-and-prognosis-of.md
  similarity: 0.375
  link: '[[2022/2022-09-procalcitonin-for-diagnosis-risk-assessment-and-prognosis-of|Procalcitonin
    for Diagnosis, Risk Assessment, and Prognosis of Respiratory Tract Infections.]]'
- title: RSVpreF (Abrysvo) and Nirsevimab-alip (Beyfortus) for the Prevention of Respiratory
    Syncytial Virus Infection.
  path: 2024/2024-06-rsvpref-abrysvo-and-nirsevimab-alip-beyfortus-for-the-preven.md
  similarity: 0.375
  link: '[[2024/2024-06-rsvpref-abrysvo-and-nirsevimab-alip-beyfortus-for-the-preven|RSVpreF
    (Abrysvo) and Nirsevimab-alip (Beyfortus) for the Prevention of Respiratory Syncytial
    Virus Infection.]]'
- title: 'Treatment and Prevention of HIV Infection: Recommendations From the International
    Antiviral Society-USA Panel.'
  path: 2024/2024-01-treatment-and-prevention-of-hiv-infection-recommendations-fr.md
  similarity: 0.375
  link: '[[2024/2024-01-treatment-and-prevention-of-hiv-infection-recommendations-fr|Treatment
    and Prevention of HIV Infection: Recommendations From the International Antiviral
    Society-USA Panel.]]'
topics:
- Infectious Disease
- Pulmonology
---

# Question ITE-2022-134

by atypical organisms such as Mycoplasma pneumoniae  and Chlamydia pneumoniae ?

## Options

**A.** 1%

**B.** 15%

**C.** 30%

**D.** 65%

**E.** 90%

## Answer

**A**

## Explanation

Acute bronchitis is caused by a viral infection in 90%â€“99% of cases. Atypical organisms such as
Mycoplasma pneumoniae  and Chlamydia pneumoniae  are rare causes and have been found in less than 1%
of cases of acute bronchitis.
Ref: Kinkade S, Long NA: Acute bronchitis. Am Fam Physician  2016;94(7):560-565.

## References

- Am Fam Physician  2016;94(7):560-565.
